KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Cash & Equivalents (2016 - 2025)

Inovio Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $36.6 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 68.61% year-over-year to $36.6 million; the TTM value through Sep 2025 reached $36.6 million, up 68.61%, while the annual FY2024 figure was $65.8 million, 359.88% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $36.6 million at Inovio Pharmaceuticals, up from $24.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $83.6 million in Q1 2021 and bottomed at $14.3 million in Q4 2023.
  • The 5-year median for Cash & Equivalents is $39.9 million (2025), against an average of $42.4 million.
  • The largest annual shift saw Cash & Equivalents crashed 72.65% in 2021 before it surged 359.88% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $71.1 million in 2021, then tumbled by 34.88% to $46.3 million in 2022, then tumbled by 69.11% to $14.3 million in 2023, then soared by 359.88% to $65.8 million in 2024, then tumbled by 44.44% to $36.6 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Cash & Equivalents are $36.6 million (Q3 2025), $24.4 million (Q2 2025), and $39.9 million (Q1 2025).